Targets › SLC7A5
5 programs from 5 companies in 5 trials: 3 Phase 1, 2 Phase 4; Oncology; next expected readout Dec 2026.
Forms a heterodimer with SLC3A2 that functions as a sodium-independent transporter for large neutral amino acids. Functions as an obligatory amino acid antiporter, mediating the exchange of amino acids and amino acid-related compounds across the plasma membrane. (UniProt, Q01650)
Open in Phaseline: the race on SLC7A5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OHSU Knight Cancer Institute | Fluciclovine PET/CT 18F-labeled amino acid PET tracer; uptake via LAT1 (large neutral amino acid transporter 1 | SLC7A5 | Phase 4 | Prostate Cancer | Dec 2026 |
| VA Greater Los Angeles Healthcare System | 18F-Fluciclovine PET/CT Amino acid PET imaging agent targeting amino acid transporters in cancer cells | SLC7A5 | Phase 4 | Prostatic Neoplasms | Nov 2027 |
| Heron Neutron Medical | F18 FBPA Radiolabeled phenylalanine analog with uptake facilitated by L-type amino acid transporter | SLC7A5 | Phase 1 | Solid Tumor | Dec 2026 |
| Abramson Cancer Center at Penn Medicine | Fluoroglutamine [18F]F-GLN 18F-labeled glutamine PET imaging agent | SLC7A5 | Phase 1 | Breast Cancer | Dec 2026 |
| Brigham and Women's Hospital | 18F-fluciclovine Amino acid transporter targeting radiotracer | SLC7A5, SLC7A8 | Phase 1 | Advanced Prostate Cancer | Sep 2027 |
Breast Cancer (1) Prostate Cancer (1) Advanced Prostate Cancer (1) Prostatic Neoplasms (1) Solid Tumor (1)
small molecule (5)
Abramson Cancer Center at Penn Medicine (1) OHSU Knight Cancer Institute (1) Brigham and Women's Hospital (1) VA Greater Los Angeles Healthcare System (1) Heron Neutron Medical (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.